2025 fourth_quarter Filing
Q4Expenses
$230K
Method: A
Filed
January 21, 2026
Lobbying Activities
Health IssuesView all
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; Pharmacy benefit manager reform legislation; Issues related to Most Favored Nation (MFN) pricing models
Contacted:Executive Office of the President (EOP), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
AccountingView all
Engaged with the Securities and Exchange Commission on a regulatory matter
Contacted:Securities & Exchange Commission (SEC)
Lobbyists (1)
JOHN PAUL HALLIWELL